This requires a more rigorous approach to healthcare spending decisions in other sectors of the industry. A final barrier to use of RUVs is the widely-held perception among Canadians that selleck products if a vaccine will benefit them individually it will be provided to them at no cost. This reluctance to pay for vaccines is rooted in history but stands in sharp contrast to many other recommended personal preventive measures that Canadians must pay for such as statin drugs, infant

car seats, sunscreens, and bicycle helmets. Studies to examine attitudes of health professionals and the public about purchasing vaccines and how to modify them are urgently needed. Central to success will be a better understanding of what motivates individuals to accept a vaccine [45] and [46] and how best to market vaccines to individual consumers. The public is increasingly health conscious and heeds other user-pay prevention advice.

Optimal roles of public health, professional organizations/collaborations and the vaccine industry in educating the public need to be clarified, including the role and Crenolanib chemical structure ethics of direct-to-consumer advertising by any of these stakeholders. The greatest need is to change the widespread perception that vaccines should be publicly funded or ignored. The long-standing and total dominance of population over individual considerations for vaccines needs to end or the potential benefits of some vaccines will not be realized, to the detriment of those at risk. It is a form of discrimination against vaccines compared with (preventive) drugs that urgently needs to be corrected. This article is based on a Workshop on Recommended but Unfunded Vaccines sponsored by Canadian Association for Immunization Research and Evaluation (CAIRE) in Ottawa on November 2-3, 2012. The 38 Canadian participants included family physicians, pediatricians, internists, infectious diseases

specialists, an obstetrician/gynecologist, an ethicist, an insurance specialist, officials of regional, provincial and federal public health departments, nearly and representatives of the vaccine industry, whose contributions we gratefully acknowledge. Conflict of interest: The opinions, results, and conclusions reported in this paper are those of the authors. No endorsement by the Ontario Agency for Health Protection and Promotion is intended or should be inferred. “
“Combination vaccines against diphtheria, tetanus and pertussis (DTP) represent the core of global childhood vaccination programs. The introduction of hepatitis B (HepB) virus and Haemophilus influenzae type b (Hib) vaccinations into the Expanded Program on Immunization (EPI) in the 1990s has ensured that >70% of the targeted population receives the necessary vaccines [1]; yet, in 2009 over 23 million children worldwide still did not receive all three DTP doses [2], and vaccine coverage for HepB and Hib was at sub-optimal levels in many countries.